Search Results
Your search for ,New matches 16919 pages
Showing 2701 - 2750ASCO Celebrates the Cancer Moonshot on Its Relaunch Anniversary
“Dedicated to making a world of difference in cancer care, the American Society of Clinical Oncology and its affiliated organization, the American Association of Clinical Oncology (ASCO), laud the goals, progress, and continued potential of the Cancer Moonshot initiative. Having the full support of ...
Idecabtagene Vicleucel vs Standard Regimens in Patients With Relapsed or Refractory Multiple Myeloma
As reported in The New England Journal of Medicine by Paula Rodriguez-Otero, MD, PhD, of Clínica Universidad de Navarra, Pamplona, Spain, and colleagues, an interim analysis of the phase III KarMMa-3 trial has shown superior progression-free survival with the B-cell maturation antigen–directed...
Rucaparib vs Physician’s Choice of Single-Agent Therapy in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
As reported in The New England Journal of Medicine by Karim Fizazi, MD, PhD, of Gustave Roussy Institute, Paris-Saclay University, and colleagues, the phase III TRITON3 trial has shown significantly improved progression-free survival with rucaparib vs physician-selected single-agent therapy in the...
Sacituzumab Govitecan-hziy Achieves Response After Disease Progression on Immune Checkpoint Inhibitor in Metastatic Urothelial Cancer
Treatment with the antibody-drug conjugate sacituzumab govitecan-hziy achieved an objective response rate of 32% in platinum-ineligible patients with metastatic urothelial cancer who experienced disease progression on an immune checkpoint inhibitor, according to the primary analysis of the...
Colorectal Cancer Rates Are Rising in Younger Adults, Shifting to More Advanced Disease Across All Ages
According to the American Cancer Society, colorectal cancer is the third most commonly diagnosed cancer and the third most common cause of cancer-related death in both men and women in the United States. However, it ranks second in cancer-related deaths overall and is the leading cause of cancer...
I Haven’t Known a Life Without von Hippel-Lindau Disease
Von Hippel-Lindau (VHL) disease has been with me since I was 5 years old, when a benign tumor was found on the optic nerve of my left eye, leaving me blind in that eye. But I didn’t get an official diagnosis of the disease until 2011, when I was 20. By then, it was like a light switch had turned...
Use of Low-Dose Naltrexone
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus...
Myriam Chalabi, MD, PhD, on Colon Cancer: New Findings on Neoadjuvant Immune Checkpoint Inhibition
Myriam Chalabi, MD, PhD, of The Netherlands Cancer Institute, discusses data from the NICHE-2 study, which confirms previously reported pathologic responses to short-term neoadjuvant nivolumab plus ipilimumab in patients with locally advanced mismatch repair–deficient colon cancer. Survival data...
ACCC Releases Advocacy Agenda at 49th Annual Meeting & Cancer Center Business Summit
The Association of Community Cancer Centers (ACCC) represents members nationwide from all care delivery settings. ACCC’s 49th Annual Meeting & Cancer Business Summit was held March 8–10, 2023, in Washington, DC, where the society released its advocacy agenda for 2023. Areas of Focus ACCC...
Early Exposure to Health-Care Inequities Sets the Stage for a Leadership Role in Global Oncology for Satish Gopal, MD, MPH
In this installment of The ASCO Post’s Global Oncology series, guest editor, Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Satish Gopal, MD, MPH, Director of the Center for Global Health at the National Cancer Institute (NCI). In this role, he oversees the development of initiatives and...
Northwell Health Names Richard D. Carvajal, MD, to Lead Medical Oncology Programs
Northwell Health has appointed Richard D. Carvajal, MD, a clinician and researcher in melanoma and early-phase drug development, as Deputy Physician-in-Chief and Director of Medical Oncology at the Northwell Health Cancer Institute. He also was named the R. J. Zuckerberg Chair in Medical Oncology....
Rangaswamy Govindarajan, MD, Named Chief of UAMS Hematology and Oncology Division
The University of Arkansas for Medical Sciences (UAMS) recently announced the appointment of Rangaswamy Govindarajan, MD, as Chief of the Division of Hematology and Oncology at the UAMS Winthrop P. Rockefeller Cancer Institute. Dr. Govindarajan, who is also Professor in the division, will lead a...
Cleveland Clinic Opens New Cancer Center in Abu Dhabi
Cleveland Clinic has announced the opening of a new state-of-the-art cancer facility, named the Fatima bint Mubarak Center, at Cleveland Clinic Abu Dhabi. “[This] marks the next step in fulfilling our mission to provide compassionate, complex care in the United Arab Emirates [UAE)]” said Tom...
Zanubrutinib Improves Progression-Free Survival vs Ibrutinib in Relapsed or Refractory CLL or SLL
As reported in The New England Journal of Medicine by Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute and Harvard University, and colleagues, the phase III ALPINE trial has shown significantly better progression-free survival with zanubrutinib, a Bruton’s tyrosine kinase (BTK)...
Walks on a Beach With an Inspiring Grandfather Led to a Career in Cancer Research and Drug Development for Vivek Subbiah, MD
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Vivek Subbiah, MD, Center Clinical Medical Director of the Clinical Center for Targeted Therapy, Cancer Medicine Division, at The University of Texas MD Anderson Cancer Center, ...
GLOW Trial: Zolbetuximab Plus CAPOX Extends Survival in Gastric Cancer Subtype
First-line treatment with zolbetuximab in combination with capecitabine and oxaliplatin (CAPOX) extended overall survival in patients with claudin-18.2 (CLDN18.2)-positive/HER2-negative locally advanced or metastatic gastric adenocarcinoma, according to results of the GLOW trial reported by Xu et...
Expert Point of View: Monica Chatwal, MD
Medical oncologist Monica Chatwal, MD, of Moffitt Cancer Center, Tampa, Florida, commented on the take-home points from the ARASENS trial. “The ARASENS trial continues to show a survival benefit for a triplet therapy approach in metastatic hormone-sensitive prostate cancer with androgen-deprivation ...
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
The addition of the androgen receptor inhibitor darolutamide to androgen-deprivation therapy and docetaxel reduced the risk of death by 30% compared with androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer, according to a post hoc analysis of...
Study Examines Effect of Physical Activity on Recurrence in Patients Previously Treated for Colorectal Cancer
Researchers have found that postoperative physical activity was associated with improved disease-free survival among patients previously treated for stage III colorectal cancer, according to a novel study published by Brown et al in the British Journal of Sports Medicine. “With March being National ...
Patricia M. LoRusso, DO, PhD (hc), Elected 2023–2024 AACR President-Elect
The members of the American Association for Cancer Research (AACR) have elected Patricia M. LoRusso, DO, PhD (hc), as the President-Elect for the 2023 to 2024 term. Dr. LoRusso will become President-Elect on Monday, April 17, during the Annual Business Meeting of Members at the AACR Annual Meeting...
Nuances in Breast Cancer Imaging for Screening and Surveillance
Breast cancer screening and imaging-based surveillance after treatment remain suboptimal, largely because of confusion in the guidelines and the fact that dense breasts are too often ignored, according to Elizabeth Morris, MD, FACR, FSBI, FISMRM, Professor and Chair of the Department of Radiology...
Cancer Diagnostic Services Offered at a Community Health Center May Speed Diagnoses for Underserved Patients
In a new colocation model for cancer diagnostic services, researchers have found that a new program installed at a community health center that cares for historically underserved populations was able to reduce the time to cancer diagnosis from a median of 32 days to 12 days, according to an article ...
ACCC Releases 2022 Impact Report
The Association of Community Cancer Centers (ACCC)—which represents more than 34,000 multidisciplinary oncology practitioners—outlined successful programs and initiatives in 2022 that advanced oncology care, according to the ACCC's 2022 Impact Report. These new programs and initiatives included...
Active Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer: 15-Year Outcomes in the UK ProtecT Trial
As reported in The New England Journal of Medicine by Freddie C. Hamdy, FRCS(Urol), FMedSci, and colleagues, 15-year follow-up of the UK phase III ProtecT trial has shown no significant difference in prostate cancer mortality with active monitoring, surgery, or radiotherapy for patients with...
Pembrolizumab Plus Ifosfamide, Carboplatin, and Etoposide in Relapsed or Refractory Classical Hodgkin Lymphoma
In a phase II trial reported in JAMA Oncology, Locke J. Bryan, MD, and colleagues found that the combination of pembrolizumab with ICE chemotherapy (a regimen including ifosfamide, carboplatin, and etoposide) produced a high rate of complete response in patients with relapsed or refractory...
Does Discrimination Accelerate Aging in Black Cancer Survivors?
Investigators have found that Black cancer survivors who reported high levels of discrimination showed greater biological aging and frailty than those who reported lower levels of discrimination, according to a new study published by Mandelblatt et al in the journal Cancer. Background...
Trust in Cancer Information May Have Declined Among Black Individuals During COVID-19 Pandemic
Investigators have found that Black individuals’ trust in information provided by the government on cancer fell by almost 50% during the COVID-19 pandemic, according to a new study published by Bispo et al in the Journal of Health Communication. The investigators stressed the need to assess whether ...
Study Reveals Potential Cause of Resistance to Revumenib in Patients With Acute Myeloid Leukemia
Use of the novel menin inhibitor revumenib has led to remissions in patients with acute myeloid leukemia (AML), and associated findings have suggested the mechanisms through which cancer cells may become resistant to such treatment, according to two studies published by Issa et al and Perner et al, ...
Neoadjuvant Dual Immunotherapy Plus Chemotherapy Improves Patient Outcomes in Operable Lung Cancer
In the phase II NEOSTAR trial, adding ipilimumab to a neoadjuvant combination of nivolumab plus platinum-based chemotherapy resulted in a major pathologic response in half of all treated patients with early-stage, resectable non–small cell lung cancer (NSCLC). New findings from the NEOSTAR study,...
Detection of Emphysema During Lung Cancer Screening
In an article published in Annals of the American Thoracic Society, James L. Mulshine, MD, and colleagues maintained that the high frequency of emphysema newly identified during low-dose computed tomography (CT) lung cancer screening presents an important opportunity to engage individuals with such ...
FDA Approves Dabrafenib/Trametinib for Pediatric Patients With BRAF V600E–Mutated Low-Grade Glioma
On March 16, 2023, the U.S. Food and Drug Administration (FDA) approved dabrafenib (Tafinlar) with trametinib (Mekinist) for pediatric patients aged 1 year and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy. The FDA also approved new oral formulations of both...
Vitamin A and Risk for Pancreatitis During Chemotherapy for ALL
Consuming a diet rich in vitamin A or its analogs may help prevent pediatric and young adult patients with acute lymphoblastic leukemia (ALL) reduce their risk of developing pancreatitis during chemotherapy, according to a recent study by Tsai et al in Science Translational Medicine. Background For ...
Gut Microbiome May Influence How Patients With Non-Hodgkin Lymphoma Respond to CAR T-Cell Therapy
Researchers have revealed how microorganisms in the gut may influence the outcomes of patients with non-Hodgkin lymphoma undergoing chimeric antigen receptor (CAR) T-cell therapy, according to a study published by Stein-Thoeringer et al in Nature Medicine. Background Microorganisms live in or on...
Racial Inequalities in Prostate Cancer Care May Be Associated With Facility-Level Disparities
Racial minorities in the United States may be less likely to receive treatment for prostate cancer and, overall, have worse survival outcomes compared with individuals who are White, according to a new study published by Nguyen et al in Urologic Oncology. Typically, patient-level and...
COVID-19 Vaccination Rates May Be Lower in Patients With Cancer Who Have Comorbidities, Certain Types of Cancer, and Specific Sociodemographic Factors
Investigators have found that patients undergoing treatment for cancer who have comorbidities, metastatic solid or non–B-cell hematologic malignancies, and those living in areas with lower levels of education and higher levels of unemployment may have lower rates of COVID-19 vaccination, according...
New Research Highlights the Negative Impact of Continued Exclusion of Patients With African Ancestry From Research on Cancer Genomics
Researchers have revealed how the lack of genomic research for individuals with African ancestry—particularly those from the Sub-Saharan region—may be hampering efforts to reduce disparities for patients with prostate cancer, according to a new study published by Gheybi et al in JNCCN–Journal of...
Elizabeth Smyth, MD, Offers Insight on KEYNOTE-859 Findings
The invited discussant of KEYNOTE-859,1 Elizabeth Smyth, MD, consultant in gastrointestinal oncology at Cambridge University Hospitals NHS Foundation Trust in the United Kingdom, called the findings “practice-changing” but cautioned that better patient selection is needed to optimally apply them....
KEYNOTE-859 Interim Analysis: Overall Survival Benefit for First-Line Pembrolizumab in Advanced Gastric Cancer
Results of the interim analysis of KEYNOTE-859 are in, and they confirm the overall survival benefit of first-line immunotherapy plus chemotherapy in advanced gastric cancer.1 Pembrolizumab plus a fluoropyrimidine- and platinum-containing doublet provided a statistically significant improvement in...
Involving Hospitalists in Inpatient Cancer Care May Reduce Patient Stays, Oncologist Stress
Introducing hospitalists to cancer care comanagement may be associated with decreased lengths of hospital stays for patients, increased inpatient hospital capacity, and reduced stress levels among oncologists—all while maintaining high-quality inpatient care, according to a new study published by...
Delaying Treatment for Patients With Localized Prostate Cancer May Not Increase Mortality Risk, ProtecT Trial Shows
Patients with prostate cancer who undergo active monitoring may experience the same 15-year survival rates as those who undergo radiotherapy or surgery, according to new findings published by Hamdy et al in The New England Journal of Medicine and simultaneously presented at the 2023 European...
Novel Urine Test May Play a Role in Bladder Cancer Prediction
Testing for genetic mutations in urine may help clinicians detect bladder cancer years before the disease shows clinical symptoms, according to new findings presented by Le Calvez-Kelm et al at the 2023 European Association of Urology Annual Congress (Abstract A0268). The researchers identified...
New Technique May Reduce Postoperative Complications in Prostate Cancer Surgery
Researchers have found that a novel technique used during prostate cancer surgery may reduce the risk of postoperative lymphocele by 50%, according to new findings presented by Neuberger et al at the 2023 European Association of Urology Annual Congress (Abstract A0656). The technique—involving the...
FDA Issues Safety Communication on Reports of Squamous Cell Carcinoma in the Capsule Around Breast Implants
On March 8, the U.S. Food and Drug Administration (FDA) provided an update on reports of squamous cell carcinoma (SCC) in the scar tissue, or capsule, that forms around breast implants. Previously, on September 8, 2022, the FDA released a safety communication informing the public of reports of...
Digital Rectal Examination Fails to Detect Early Prostate Cancer, Study Shows
A common method of detecting prostate cancer may not be accurate enough to serve as a reliable screening tool by itself, researchers have warned. The digital rectal exam (DRE), in which health-care providers check the prostate gland with a finger for unusual swelling or lumps in the rectum, is...
Study Reveals New Understanding of How Androgen Therapy Affects Breast Tissue
Molecular changes observed in the breast tissue of transgender men undergoing androgen therapy may signal the potential for also using the hormone to prevent or treat estrogen receptor–positive breast cancer. The findings were published by Raths et al in Cell Genomics. “These findings build upon...
Nirogacestat May Benefit Patients With Desmoid Tumors
As reported in The New England Journal of Medicine by Gounder et al, the phase III DeFi trial has shown significant improvement in progression-free survival with the investigational oral γ-secretase inhibitor nirogacestat vs placebo in patients with desmoid tumors. As noted by the investigators,...
Miguel-Angel Perales, MD, Named 2023–2024 President of ASTCT
The American Society for Transplantation and Cellular Therapy (ASTCT) has chosen Miguel-Angel Perales, MD, as President of the Society in 2023–2024. Dr. Perales first served on the Board of Directors in 2017 and has been a member of ASTCT since 2001. He is Chief of the Adult Bone Marrow...
I’m Doing My Part to Erase the Stigma Surrounding Lung Cancer
Ironically, I received a diagnosis of lung cancer when I was feeling my healthiest. In December 2015, when I was just 51 years old, a routine chest x-ray found a small shadow on the lower lobe of my right lung. Despite being a never-smoker, a regular exerciser, and a healthy eater, my primary care...
Cancer Mortality Decreased 33% in Newest Data Reported by the American Cancer Society
Overall cancer mortality rates have decreased 33% since 1991, and cervical cancer incidence decreased 65% from 2012 through 2019, according to the latest statistics reported by the American Cancer Society (ACS).1 Amid this good news, however, was a troubling 3% annual increase in prostate cancer...
Four Leading UPMC/Pitt Scientists Receive Funding for Research in Breast Cancer
Steffi Oesterreich, PhD, and Adrian V. Lee, PhD, breast cancer researchers at UMPC Hillman Cancer Center and Magee-Womens Research Institute, along with Wendie Berg, MD, PhD, Professor of Radiology at UMPC Magee-Womens Hospital, all of the University of Pittsburgh School of Medicine, have received ...
